Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers.
Timothy P DiPeriKurt W EvansMaria Gabriela RasoMing ZhaoYasmeen Q RizviXiaofeng ZhengBailiang WangBryce P KirbyKathleen KongMichael KahleTimothy Anthony YapEcaterina E DumbravaJaffer A AjaniSiqing FuKhandan KeyomarsiFunda Meric-BernstamPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
We provide rationale for combining T-DXd with adavosertib in HER2-expressing cancers, especially with co-occuring CCNE1 amplifications.